Every Form 4 that DAXOR CORP (DXR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXR filings page.
DAXOR CORP (symbol: DXR) is the issuer of record for a Form 4 filing submitted to the SEC.
Daxor Corp reported that its Chief Financial Officer, Michel Robert J, received a compensation-related stock grant. He was awarded 12,000 shares of Daxor Common Stock at no purchase price, which are scheduled to vest on June 23, 2026. Following this grant, he directly holds 33,050 shares of the company’s common stock. This is a non-market transaction classified as a grant or award acquisition rather than an open-market share purchase.
Feldschuh Michael Richard reported acquisition or exercise transactions in this Form 4 filing.
DAXOR CORP Chief Executive Officer Michael Richard Feldschuh reported receiving a grant of 30,000 shares of Daxor Common Stock. The award was recorded at a price of $0.00 per share and is compensation-related rather than an open-market purchase. According to a footnote, the 30,000 granted shares vest on June 23, 2026. After this grant, Feldschuh directly holds a total of 243,694 shares of Daxor Common Stock.
Feldschuh Jonathan Adam reported acquisition or exercise transactions in this Form 4 filing.
DAXOR CORP Chief Scientific Officer Jonathan Adam Feldschuh received an equity grant of 25,000 shares of Daxor common stock. The shares were granted at a price of $0.00 per share as a stock award rather than an open-market purchase.
According to the filing, Feldschuh now holds a total of 78,908 Daxor common shares directly after this award. A footnote states that the 25,000 granted shares vest on June 23, 2026, meaning they become fully earned on that date if applicable conditions are met.
Daxor Corp director Joy S. Goudie reported receiving a grant of 2,500 stock options to buy common stock at an exercise price of $10.14 per share. The options expire on June 23, 2031 and are scheduled to vest in three annual installments from June 23, 2026 through June 23, 2028. The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
Daxor Corp director Henry D. Cremisi received a grant of stock options for 2,500 shares of common stock. The options carry an exercise price of $10.14 per share and expire on June 23, 2031. This is a compensation-related award, not an open-market trade.
The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. The options are scheduled to vest in three installments: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.
DAXOR CORP director Edward Feuer received a grant of 2,500 stock options as compensation. These options give him the right to buy common stock at an exercise price of $10.14 per share and expire on June 23, 2031.
The grant is contingent on approval by the Securities & Exchange Commission to amend the Daxor Corporation 2020 Incentive Compensation Plan. The options are scheduled to vest in three annual installments: 833 options on June 23, 2026, 833 on June 23, 2027, and 834 on June 23, 2028. After this grant, Feuer holds 2,500 stock options directly.
DAXOR CORP reported that director-level insider Caleb DesRosiers received a grant of stock options for 2,500 shares of common stock at an exercise price of $10.14 per share. These options are contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan and will vest in three annual installments through June 23, 2028.
DAXOR CORP Chief Executive Officer Michael Richard Feldschuh made an open-market purchase of Daxor Common Stock. On April 8, 2026, he bought 1,000 shares at a price of $9.07 per share. Following this transaction, he directly owns 213,694 Daxor Common Stock shares.
DAXOR CORP Chief Financial Officer Michel Robert J reported an open-market purchase of Daxor Common Stock. On March 31, 2026, he bought 1,000 shares at $9.90 per share, bringing his directly held stake to 21,050 shares after the transaction.
Jefferies John reported open-market purchase transactions in this Form 4 filing.
DAXOR CORP Chief Medical Officer John Jefferies acquired additional equity in the company through stock grants. He received 5,941 shares of Daxor Common Stock as compensation, including 3,656 shares that will vest on March 20, 2029 and 2,285 shares that vested on March 20, 2026. After these transactions, he directly holds 23,557 shares of Daxor Common Stock.
Daxor Corp reported an insider equity transaction by its Chief Financial Officer, Robert J. Michel. On December 9, 2025, he acquired 3,000 shares of Daxor common stock at a stated price of $0, reflecting the vesting of a stock grant.
Following this transaction, the CFO beneficially owns 20,050 shares of Daxor common stock in direct ownership, according to the Form 4 disclosure.
Daxor Corp (DXR) reported an insider equity event by its Chief Medical Officer, John Jefferies. On November 12, 2025, he acquired 2,344 shares of Daxor common stock at a reported price of $0, coded as “P,” with the filing noting these shares were from a grant that vested on November 12, 2025.
Following this transaction, Jefferies beneficially owns 17,616 shares with direct ownership. The filing was made by one reporting person and identifies his role as Officer (Chief Medical Officer).